Breaking News

EVOQ Therapeutics Secures $2 Million NIH Grant

The funds will support the development of novel therapies for autoimmune diseases.

Author Image

By: Charlie Sternberg

Associate Editor

EVOQ Therapeutics Inc., a biopharmaceutical company dedicated to the treatment of autoimmune diseases, has received a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases.   The NIH award represents an endorsement of EVOQ’s approach to harnessing the power of the immune system to treat and prevent autoimmune diseases.   “We are thrilled to receive this NIH grant, which underscores the potential of our NanoDisc technology...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters